Please assess the completion status of the following clinical trial:

Trial Title: Calcium Chloride for Prevention of Uterine Atony During Cesarean

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Pregnant female subjects at Lucile Packard Children's hospital / Stanford hospital undergoing Cesarean will be screened for inclusion in the study based upon presence of at least 2 risk factors for uterine atony/ postpartum hemorrhage. The risk factors include the following:~* intrapartum Cesarean delivery~* failed operative vaginal delivery with forceps or vacuum~* magnesium infusion~* chorioamnionitis~* multiple gestation~* polyhydramnios~* preterm delivery \<37 weeks~* prior history of postpartum hemorrhage~* labor induction or augmentation with oxytocin~* advanced maternal age~* obesity with body mass index \>40~Exclusion Criteria:~* a degree of case urgency to which taking time to consent for the study could compromise patient care, determined by anesthesiologist or obstetrician~* patient age \<18 years or \>50 years~* renal dysfunction with serum Creatinine \> 1.0~* abnormal cardiac function or history of arrhythmia~* patient taking digoxin~* patient currently taking a calcium channel blocker for a cardiovascular indication

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Calcium Chloride (Type: EXPERIMENTAL): Non-participating anesthesiologist prepares the drug solution, which is 1 gram of calcium chloride diluted into a total volume of 60 milliliters normal saline, labeled only with the study ID number. The solution is administered intravenously utilizing an Alaris syringe pump and microbore tubing, with infusion starting immediately at the time of fetal delivery at a rate of 360 milliliters per hour (for a calcium infusion rate of 100 milligrams /minute until the full 1 gram dose is administered).~This is a one-time administration. Patients continue to receive all standard care during the Cesarean including 1 unit oxytocin bolus at the time of fetal delivery + continuous oxytocin infusion at 7.5 units per hour per our institution's protocol.
- Placebo (Type: PLACEBO_COMPARATOR): Non-participating anesthesiologist prepares the placebo solution, which is 60 milliliters normal saline, labeled only with the study ID number. The solution is administered intravenously utilizing an Alaris syringe pump and microbore tubing, with infusion starting immediately at the time of fetal delivery at a rate of 360 milliliters per hour.~This is a one-time administration. Patients continue to receive all standard care during the Cesarean including 1 unit oxytocin bolus at the time of fetal delivery + continuous oxytocin infusion at 7.5 units per hour per our institution's protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).